Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a clear ...
Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% ...
Zacks Investment Research on MSN
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.50, moving -6.17% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.41%. At ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results